Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors01:28

Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors

Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Disorders of the Male Reproductive System01:20

Disorders of the Male Reproductive System

Men's health issues are increasingly recognized as significant, with several conditions posing common threats. Among these, testicular cancer is especially prevalent in younger men, particularly those aged 20 to 35 years. The disease often manifests as a painless mass in the testicles, sometimes accompanied by a sensation of heaviness or a dull ache.
Prostate disorders are another major concern. These conditions can impair urinary flow due to the prostate's location around the urethra. Symptoms...
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment01:08

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
Formulation and Manufacturing Process: Physical Attributes of Generic Tablets and Capsules01:18

Formulation and Manufacturing Process: Physical Attributes of Generic Tablets and Capsules

Bioequivalence in generic drugs, such as tablets and capsules, refers to their pharmaceutical equivalence to the brand-name counterparts. However, for therapeutic equivalence, manufacturers must also consider physical attributes like size, shape, and weight (FDA Guidance for Industry, December 2003). Discrepancies in these aspects could impact patient compliance and cause medication errors. For instance, swallowing difficulties, often experienced with larger tablets or capsules, can lead to...
Male Sexual Response: Erection & Ejaculation01:17

Male Sexual Response: Erection & Ejaculation

Sexual stimulation can take various forms, such as physical touch and visual or auditory cues. When this happens, the parasympathetic reflex in the sacral portion of the spinal cord is activated. This reflex stimulates the release of nitric oxide (NO), which then dilates the arterioles in the penis, increasing blood flow to the erectile tissues - the corpora cavernosa and corpus spongiosum.
The blood filling the erectile tissues compresses the veins, which helps to prevent blood from leaving...
Dose-Response Relationship: Potency and Efficacy01:22

Dose-Response Relationship: Potency and Efficacy

The potency of a drug is the measure of its ability to produce a biological response and can be compared by looking at the half-maximum effective concentration or EC50 values of different drugs. A lower EC50 value indicates higher potency of the drug. In the dose–response curve of two antihypertensive drugs, candesartan and irbesartan, a significant difference is observed in their EC50 values. A lower EC50 value for candesartan indicates that it is more potent than irbesartan, as it produces...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Real-World Data on Barrigel and SpaceOAR Rectal Spacers in Prostate Cancer Radiation Therapy: A Comparative Analysis.

Advances in radiation oncology·2026
Same author

Holding a Mirror to Ourselves: Remediation Policy in Surgical Training in Australia and Aotearoa New Zealand.

ANZ journal of surgery·2026
Same author

"We Don't Want You to Be Dismissed": Perspectives of Remediation From Surgical Education and Training Managers.

ANZ journal of surgery·2025
Same author

Common incidental urological lesions on computed tomography images: What to do with renal and adrenal computed tomography incidentalomas in a primary care setting.

Australian journal of general practice·2024
Same author

"A clean slate": Insights for improving remediation from the perspectives of underperforming surgical trainees.

American journal of surgery·2024
Same author

Supervisors-Unappreciated and under supported: who pays?

ANZ journal of surgery·2024
Same journal

Occupational violence and staff safety in general practice.

Australian family physician·2018
Same journal

You should get that mole checked out: Ethical and legal considerations of the unsolicited clinical opinion.

Australian family physician·2018
Same journal

Understanding the decision to commence a dose administration aid.

Australian family physician·2018
Same journal

Psychological distress and risky sexual behaviours among women aged 16-25 years in Victoria, Australia.

Australian family physician·2018
Same journal

A mixed-methods feasibility study of routinely weighing patients in general practice to aid weight management.

Australian family physician·2018
Same journal

The Australian Mid-West Coastal Marine Wound Infections Study.

Australian family physician·2018
See all related articles

Related Experiment Video

Updated: Jun 12, 2026

Treatment Model for Young Patients with Psychogenic Erectile Dysfunction and Resultant Infertility
04:22

Treatment Model for Young Patients with Psychogenic Erectile Dysfunction and Resultant Infertility

Published on: May 30, 2025

Erectile dysfunction - when tablets don't work.

Ian A R Smith1, Nicholas McLeod, Prem Rashid

  • 1Liverpool Hospital, Sydney, and Faculty of Medicine, University of Western Sydney and University of New South Wales, Australia. ianandvanessa@live.com.au

Australian Family Physician
|May 21, 2010
PubMed
Summary
This summary is machine-generated.

Erectile dysfunction (ED) affects 40% of Australian men and is linked to cardiovascular issues. Management progresses from lifestyle changes and PDE-5 inhibitors to injections, devices, or implants for persistent cases.

Related Experiment Videos

Last Updated: Jun 12, 2026

Treatment Model for Young Patients with Psychogenic Erectile Dysfunction and Resultant Infertility
04:22

Treatment Model for Young Patients with Psychogenic Erectile Dysfunction and Resultant Infertility

Published on: May 30, 2025

Area of Science:

  • Urology
  • Andrology
  • General Practice

Background:

  • Erectile dysfunction (ED) is a prevalent clinical issue encountered in general practice.
  • While phosphodiesterase-5 (PDE-5) inhibitors are effective for many, a subset of patients requires advanced treatment options.

Purpose of the Study:

  • To provide a comprehensive overview of erectile dysfunction (ED).
  • To focus on the management strategies for patients unresponsive to oral therapies.

Main Methods:

  • Literature review on ED prevalence, risk factors, and treatment modalities.
  • Analysis of current clinical guidelines for ED management.
  • Discussion of second and third-line treatment options beyond oral agents.

Main Results:

  • Erectile dysfunction (ED) is multifactorial, affecting approximately 40% of Australian men.
  • ED incidence correlates with age and shares risk factors with cardiovascular and metabolic diseases.
  • Successful ED management involves addressing cardiovascular health, lifestyle modifications, and appropriate therapeutic sequencing.

Conclusions:

  • Initial ED management should include cardiovascular risk assessment, lifestyle advice, and a trial of PDE-5 inhibitors.
  • Second-line treatments comprise intracavernosal injections and vacuum erection devices.
  • Third-line therapy involves penile implants, with success influenced by partner involvement, patient selection, and ongoing support.